Gregory Davis

About

Gregory Davis is the Vice President and Head of Technology at Sangamo Therapeutics in the United States. His research primarily focuses on epigenetic control mechanisms and gene editing technologies, as demonstrated in his recent articles on the use of lentiviral vectors for gene regulation and advanced base editing techniques. He also explores microbial interactions in the human gut, utilizing CRISPR technology to investigate glycan utilization strategies in gnotobiotic mice.